pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$OCULOCULAR THERAPEUTIX, INC

$OCUL6.0100-3.22%
Bedford, MA, USupdated 7h ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
2
marketed
1
phase 3
1
catalysts ytd
9
approvals ytd
1
recalls ytd
2

Pipeline(2)

pipeline depth2 products
Phase 3: 1Marketed: 1
1Phase 31Marketed
Marketed
axitinib SR
Wet (Neovascular / Exudative) Macular Degeneration
Vascular endothelial growth factor receptor
Phase 3
dexamethasone SR
Ocular Inflammation
Glucocorticoid receptor

📅 Upcoming

Feb 4, 2027
earnings
$OCUL6.0100-3.22%
in 3mo
OCULAR THERAPEUTIX, INC earnings
OCULAR THERAPEUTIX, INC
→

🕒 Recent(90d)

earnings (2)
Nov 9, 2026
earnings
$OCUL6.0100-3.22%
8d ago
OCULAR THERAPEUTIX, INC earnings
OCULAR THERAPEUTIX, INC
→
Nov 4, 2026
earnings
$OCUL6.0100-3.22%
13d ago
OCULAR THERAPEUTIX, INC earnings
OCULAR THERAPEUTIX, INC
→
view all catalysts →

Active trials

  • phase2A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)completedn=83
  • phase3Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Studynot yet recruitingn=850
  • phase3A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathyrecruitingn=930
  • phase3Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degenerationactive not recruitingn=825
  • phase3Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degenerationactive not recruitingn=344
  • phase1CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertensioncompletedn=19
  • phase1CLN-0046: Treatment of AMD Subjects With OTX-TKIcompletedn=29
  • phase2OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)completedn=100
🐶 Hiring Signal
next earnings Feb 4, 2027
No open roles indexed yet — view OCULAR THERAPEUTIX, INC jobs →

News

  • STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more
    Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness fell short of its primary goal
    stat · 3mo ago
  • STAT+: Eyepoint study results for vision treatment disappoint, but company still sees promise
    Eyepoint said patients given its experimental treatment for wet AMD failed to maintain vision with less frequent injections compared to a standard treatment.
    stat · 3mo ago
  • EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD race
    EyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.
    biospace · 3mo ago
identifiers
ticker
$OCUL
SEC CIK
0001393434
country
US
source
sec_tickers
top tags
Oncology1Ophthalmology1
mentioned in
3news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 58m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?